제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구 (Comparisons of Adherence, Efficacy and Price between Sitagliptin/Metformin Fixed-dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Type 2 Diabetes Mellitus Patien)

서지정보

· 발행기관 : 한국임상약학회
· 수록지 정보 : 한국임상약학회지 / 24권 / 3호 / 193 ~ 198페이지
· 저자명 : 박지혜, 곽혜선, 이병구, 김재연

초록

Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combinationtablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2diabetes mellitus. Methods: Adherence was measured as the medication possession ratio (MPR) of ≥80%, and MPRwas calculated as the number of total prescription days divided by the total treatment period. Hemoglobin A1C (HbA1c)differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved HbA1c lessthan 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metforminand sitagliptin/metformin tablets were investigated. Results: More than 90% of patients showed adherence inboth groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was nostatistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutivetimes tended to be somewhat higher in fixed dose combination group than in concomitant administration groupwithout a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin wascheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration. Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was notsignificantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixeddosecombination tablets were cheaper than concomitant administration of each tablet.

영어초록

Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combinationtablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2diabetes mellitus. Methods: Adherence was measured as the medication possession ratio (MPR) of ≥80%, and MPRwas calculated as the number of total prescription days divided by the total treatment period. Hemoglobin A1C (HbA1c)differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved HbA1c lessthan 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metforminand sitagliptin/metformin tablets were investigated. Results: More than 90% of patients showed adherence inboth groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was nostatistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutivetimes tended to be somewhat higher in fixed dose combination group than in concomitant administration groupwithout a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin wascheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration. Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was notsignificantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixeddosecombination tablets were cheaper than concomitant administration of each tablet.

참고자료

· 없음